Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|October 9, 2017
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specificationDaniel Moj, Hannah Britz, Jürgen Burhenne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2010
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysisAntonia Dimitrakopoulou-Strauss, Ludwig G Strauss, Gerlinde Egerer, et al.
European Journal of Haematology|January 22, 2020
Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin's lymphomaXiang Zhou, Patrick Wuchter, Gerlinde Egerer, et al.
European Journal of Haematology|July 25, 2019
Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphomaXiang Zhou, Patrick Wuchter, Gerlinde Egerer, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 26, 2024
Microbiological risk factors, ICU survival, and 1-year survival in hematological patients with pneumonia requiring invasive mechanical ventilationBenjamin Seybold, Timo Funk, Peter Dreger, et al.
BMC Infectious Diseases|June 24, 2010
Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registryJohan Maertens, Gerlinde Egerer, Wan Shik Shin, et al.
Basic & Clinical Pharmacology & Toxicology|July 11, 2018
Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditionsMarcus J P Geist, Gerlinde Egerer, Gerd Mikus, et al.
Onkologie|March 7, 2008
Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomographyBernd Kasper, Sascha Dietrich, Antonia Dimitrakopoulou-Strauss, et al.
Digestive Diseases (Basel, Switzerland)|May 16, 2006
Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in HeidelbergBernd Kasper, Birgit Kallinowski, Thomas Herrmann, et al.
International Journal of Cancer|July 13, 2002
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Pageof 11